Company Description
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally.
The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus.
It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions.
It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health.
Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.
| Country | United States |
| Founded | 1991 |
| IPO Date | Oct 5, 1995 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 2,700 |
| CEO | Paul J. Diaz |
Contact Details
Address: 322 North 2200 West Salt Lake City, Utah 84116 United States | |
| Phone | 801-584-3600 |
| Website | myriad.com |
Stock Details
| Ticker Symbol | MYGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000899923 |
| CUSIP Number | 62855J104 |
| ISIN Number | US62855J1043 |
| Employer ID | 87-0494517 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Paul J. Diaz | Chief Executive Officer, President and Director |
| Dr. Kevin Richard Haas Ph.D. | Chief Technology Officer |
| Mark S. Verratti | Chief Commercial Officer |
| Scott J. Leffler | Chief Financial Officer |
| Samraat S. Raha | Chief Operating Officer |
| Natalie Munk | Principal Accounting Officer |
| Dr. Dale Muzzey Ph.D. | Chief Scientific Officer |
| Matthew Scalo | Senior Vice President of Investor Relations |
| Glenn Farrell | Senior Vice President and Chief Marketing Officer |
| Shereen Solaiman | Chief People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2024 | ARS | Filing |
| Apr 17, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 17, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 10, 2024 | 144 | Filing |
| Mar 18, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 28, 2024 | 10-K | Annual Report |
| Feb 27, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |